BioArctic AB (publ) - Asset Resilience Ratio

Latest as of September 2025: 72.35%

BioArctic AB (publ) (BIOA-B) has an Asset Resilience Ratio of 72.35% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BioArctic AB (publ) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

Skr1.88 Billion
≈ $202.53 Million USD Cash + Short-term Investments

Total Assets

Skr2.60 Billion
≈ $279.92 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how BioArctic AB (publ)'s Asset Resilience Ratio has changed over time. See BIOA-B net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down BioArctic AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BioArctic AB (publ) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr1.10 Billion 42.47%
Short-term Investments Skr777.36 Million 29.89%
Total Liquid Assets Skr1.88 Billion 72.35%

Asset Resilience Insights

  • Very High Liquidity: BioArctic AB (publ) maintains exceptional liquid asset reserves at 72.35% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

BioArctic AB (publ) Industry Peers by Asset Resilience Ratio

Compare BioArctic AB (publ)'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Argen-X
F:1AE
Biotechnology 25.67%
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
Biotechnology 0.21%
R&G PharmaStudies Co. Ltd. A
SHE:301333
Biotechnology 35.96%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.48%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 70.49%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%

Annual Asset Resilience Ratio for BioArctic AB (publ) (2017–2024)

The table below shows the annual Asset Resilience Ratio data for BioArctic AB (publ).

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 70.07% Skr778.92 Million
≈ $83.82 Million
Skr1.11 Billion
≈ $119.63 Million
+27.91pp
2023-12-31 42.16% Skr500.00 Million
≈ $53.81 Million
Skr1.19 Billion
≈ $127.64 Million
-52.35pp
2021-12-31 94.51% Skr848.40 Million
≈ $91.30 Million
Skr897.73 Million
≈ $96.61 Million
-0.70pp
2020-12-31 95.20% Skr999.94 Million
≈ $107.61 Million
Skr1.05 Billion
≈ $113.03 Million
+1.17pp
2019-12-31 94.04% Skr1.11 Billion
≈ $119.75 Million
Skr1.18 Billion
≈ $127.35 Million
+28.19pp
2018-12-31 65.85% Skr917.31 Million
≈ $98.72 Million
Skr1.39 Billion
≈ $149.91 Million
-31.51pp
2017-12-31 97.36% Skr1.11 Billion
≈ $119.49 Million
Skr1.14 Billion
≈ $122.73 Million
--
pp = percentage points

About BioArctic AB (publ)

ST:BIOA-B Sweden Biotechnology
Market Cap
$2.59 Billion
Skr24.04 Billion SEK
Market Cap Rank
#5393 Global
#71 in Sweden
Share Price
Skr323.80
Change (1 day)
+1.76%
52-Week Range
Skr172.00 - Skr364.40
All Time High
Skr377.80
About

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, … Read more